A 35-year-old man underwent a peripheral blood cell allograft from his HLA-identical sibling in October 2007 for ALL in third refractory relapse. The conditioning comprised oral busulfan (16 mg/kg) and i.v. melphalan (140 mg/m 2 ). GVHD prophylaxis comprised cyclosporine (3 mg/kg/day). The CD34 þ cell dose was 6.58 Â 10 6 per kg. Prophylaxis consisted of fluconazole, acyclovir and cefepime. Engraftment was prompt, and the early post transplant course was uneventful.
He was admitted 54 days after transplantation with abdominal pain, macroscopic hematuria with clots, dry cough and fever. He was on a low dose of prednisone. The chest X-ray revealed bilateral crackles. Hemoglobin was 10.6 g/100 ml, the WBC count was 3.2 Â 10 9 /l (83% neutrophils, 12% lymphocytes, 5% monocytes and 0% eosinophils) and the platelet count was 25 Â 10 9 /l. Kidney function was normal. CMV antigenemia was detected. History showed that he had always lived in the Amazonian basin in Brazil, had consumed untreated or unfiltered water, had suffered insect bites and did not use protective footwear.
The patient was treated with continuous bladder irrigation and broad-spectrum antibiotics, including ganciclovir. In the presence of computed tomography findings of probable invasive aspergillosis and diffuse bilateral infiltrates on the chest X-ray, liposomal amphotericin was started at the dose of 3 mg/kg daily. Hemorrhagic cystitis was resolved with supportive treatment.
The patient developed diarrhea, nausea, abdominal discomfort and anorexia, with cough and hemoptysis. Stool examinations showed Strongyloides stercoralis larvae on direct microscopy. He was treated with thiabendazole 25 mg/kg for 7 days and sputum samples for detection of S. stercoralis were collected. Combination therapy with ivermectin (200 mcg/kg/day) and thiabendazole (25 mg/kg/day) for 7 days was initiated after the stool examinations continued to be persistently positive. The gram stain indicated the presence of multiple filariform larvae of S. stercoralis in the sputum. All subsequent stool examinations were negative, and the signs and symptoms disappeared after 3 days of treatment. The patient was discharged from hospital on day 75 after PBSC transplantation to continue the treatment in the outpatient clinic. The plan was to repeat antiparasitic treatment after 21 days.
The low rates of strongyloidiasis after HSCT can be explained by routine screening for this parasite and the use of prophylactic treatment before transplantation. Examination of three or more stool samples has a sensitivity of 60-70% to detect S. stercoralis. 2, 5 In our hospital, three stool samples are examined before HSCT in all patients. Serology by ELISA can also be used to diagnose S. stercoralis. 6 In a study of sera from 164 hematological patients tested for the presence of Ab to S. stercoralis, the Ab was detected in serum using ELISA. The sensitivity, specificity, and positive and negative predictive values were 68, 89, 48 and 95%, respectively. 6 In endemic areas, the use of serology is controversial, and only a negative test is useful.
A retrospective analysis showed that the overall rate of S. stercoralis infection was 1.0 per 10 000 new cancer cases in the United States. Most of the patients (88%) were US residents. Evidence of hyperinfection syndrome was observed in two HSCT recipients who developed fatal S. stercoralis hemorrhagic alveolitis despite receiving highdose thiabendazole and ivermectin therapy. One case of alveolar hemorrhage, post-HSCT, due to strongyloides hyperinfection was recently described. Therapy with parenteral ivermectin and thiabendazole was initiated, but the patient's condition deteriorated and he died of respiratory failure and septic shock. 3 There are two other reported cases of strongyloidiasis in autologous HSCT patients, one developing fatal hyperinfection after corticosteroids. 4 They were both treated with albendazole and ivermectin.
Our patient was not neutropenic, was on low doses of corticosteroids and had received cyclosporine, which has anti-helminth activity. 5 Although there are no described cases of strongyloidosis hyperinfection while on cyclosporine, a recent report showed that three consecutive cadaveric kidney transplant recipients who were on tacrolimus died within 2 months from strongyloides hyperinfection. Two of the recipients had received their kidneys from a single cadaveric donor, wheras the third received it from a different donor. Both the donors came from areas endemic for strongyloidiasis. 7 The best way to treat strongyloidiasis is unclear. 8 Relapse is more frequent in immunocompromised patients, particularly with the use of corticosteroids. 8 Combination therapy is frequently used to treat strongyloides hyperinfection in this population of patients. 8 In the present case, the patient was treated with thiabendazole alone for 7 days without improvement of symptoms. Ivermectin was then given together with thiabendazole for 7 more days, and the stool samples became negative.
We conclude that strongyloides hyperinfection should be considered in patients with appropriate symptoms in endemic areas.
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